CBIO
CRESCENT BIOPHARMA, INC.BS score 61.6MEDIUMPHASE2 · mkt cap $581.5M · rev ttm $10.8M
drug hypothesis
CR-001 modulates Unknown - Not disclosed in filing to treat Locally Advanced or Metastatic Solid Tumors.
moa:Unknown - Not disclosed in filing
score breakdown
trial design70
base rate disconnect34
language red flags100
composite61.6
valuation analysis
market cap$581.5M
revenue ttm$10.8M
phasePHASE2
historical base rate10%
disconnect ratio1.2x
lead trialNCT07335497
meta
cik0001253689
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, single-arm trial in adult participants with locally advanced or metastatic solid tumors. Enrollment: 290 participants. No placebo control.
primary endpoint:Dose Escalation - Incidence and nature of dose-limiting toxicities (From the first dose of study drug up until approximately 1 month)
claimed differentiation
Unknown - Not disclosed in filing; no business section content provided
language red flags
- SEC filing business section contains only '6' - essentially no substantive content provided
- No mechanism of action disclosed
- No biological target disclosed
- No differentiation claims provided
- No preclinical evidence disclosed
- No stated risks disclosed
- No expected catalysts explicitly stated by company - only inferred from trial dates
- Trial design is standard Phase 1 dose-escalation with no apparent novel elements
- Information density extremely low for an SEC filing - may indicate incomplete filing or minimal operational history
company-stated risks
- None disclosed - no business section content provided in filing
upcoming catalysts
- 2026-02-17Trial start date
- 2029-02Primary completion date